MicroPort CardioFlow Medtech (HKG:2160) expects a net loss of between 30 million yuan and 60 million yuan in 2024, representing a decline of 87% to 94% from a year prior, according to a Thursday filing.
The medical device maker attributed the forecast to the advancement of commercialization of certain products, higher overseas revenue, cost management, reversal of an impairment loss on an equity investment, and fair value gains on convertible instruments.
Shares of the company were up 7% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。